Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma
MinKe He(Sun Yat-sen University), Ming Shi(Yanshan University), Qi-jiong Li(Sun Yat-sen University), JiaYing Lai(Qidong Liver Cancer Prevention Research), Wei Wei(Zhujiang Hospital), Qing Li(Nankai University), Ru-Hai Zou(Sun Yat-sen University), Min-Shan Chen(Sun Yat-sen University), Jing-Xian Shen(Sun Yat-sen University), Rong Guo(Sun Yat-sen University), GuoSheng Tan(Sun Yat-sen University), Yaojun Zhang(Sun Yat-sen University)
Cited by 8
Related Papers
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2)
|Autophagy|2017|275
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216